advertisement
Abstract #95156 Published in IGR 22-2
Pretreatment with frequent topical betamethasone in Ahmed glaucoma valve implantation
Yadgari M; Vafaei F; Sobhani S; Sheibani K; Noorizadeh FCanadian Journal of Ophthalmology 2022; 57: 270-276
OBJECTIVE: To evaluate the efficacy of pretreatment with topical betamethasone in Ahmed glaucoma valve (AGV) implantation. DESIGN: Randomized clinical trial. PARTICIPANTS: Sixty-two eyes from 62 patients undergoing AGV. METHODS: We randomly assigned patients undergoing AGV to 2 arms of the study. The case group received AGV implantation with preoperative betamethasone eye drops, and the control group did not receive preoperative betamethasone. Follow-up examinations were performed on postoperative day 1, at least weekly for 4 weeks, and then every 1 to 3 months. Our main outcome measure was the rate of success, defined as intraocular pressure (IOP) <15 mm Hg and IOP ≤18 mm Hg. RESULTS: We analyzed 62 eyes divided to case (n = 33) and control (n = 29) groups. The success rate was significantly higher in the intervention group than in the control group at 12 months postoperatively when considering either IOP < 15 or IOP < 18 mm Hg as success (p < 0.001) and also at 6 months when considering IOP < 18 mm Hg as success (p < 0.041). The reduction in the number of antiglaucoma medications used postoperatively was significantly higher in the betamethasone group at follow-up at 1 and 3 months and 1 year. CONCLUSION: Pretreatment with topical betamethasone in AGV implantations increases the success rate and reduces the need for medications.
Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Basir Eye Health Research Center, Tehran, Iran.
Full article